Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug S-4321 aims to tame overactive immune system

NCT ID NCT07455578

Recruiting now Disease control Sponsor: Seismic Therapeutic AU Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The goal is to check safety and how the drug affects the body. Participants receive multiple doses and are monitored for side effects and immune system changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema autoimmune disease cutaneous lupus erythematosus psoriasis psoriatic arthritis rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS (AD) AUTOIMMUNE DISEASES CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) PSORIASIS (PSO) PSORIATIC ARTHRITIS (PSA) RHEUMATOID ARTHRITIS (RA)

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Novatrials

    RECRUITING

    Charlestown, New South Wales, 2290, Australia

  • University of the Sunshine Coast Clinical Trials, Birtinya

    RECRUITING

    Birtinya, Queensland, 4575, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.